Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids

Diabetes, Obesity and Metabolism

Volumn 6, Issue 1, 2004, Pages 8-15

  Iannello, S ^a   Camuto, M ^a   Cavaleri, A ^a   Milazzo, P ^a   Pisano, M G ^a   Bellomia, D ^a   Belfiore, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Biguanide; Decremental lactate area; Diabetes; Family history of diabetes; Insulin resistance; Insulin sensitivity; Lactate; Metformin; Obesity; Short term treatment

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; LACTIC ACID; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FAMILY HISTORY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULINEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0742271972     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00306.x     Document Type: Article

References (41)

1. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabetes Metab Res Rev 1979; 5: 233-245.
2. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol 1989; 120: 257-265.
3. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
4. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
5. Reaven GM, Johnston P, Hollenbeck CB et al. Combined metformin-sulfanylurea treatment of patients with non-insulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992; 74: 1020-1026.
6. Johnson AB, Webster JM, Sum CF et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase in overweight type II diabetic patients. Metabolism 1993; 42: 1217-1222.
7. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
8. Stumvoll N, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
9. Fontbonne A, Charles MA, Juhan-Vague I et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19: 920-926.
10. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
11. Bell PM, Hadden DR. Metformin. Endocrinol Metab Clin North Am 1997; 26: 523-537.
12. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99-110.
13. UK Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients, with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
14. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
15. Rains SGH, Wilson GA, Richmond W, Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. J R Soc Med 1989; 82: 93-94.
16. Jeppensen J, Zhon MY, Chen YD, Reaven GM. Effect of metformin on post-prandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994; 17: 1093-1099.
17. Perriello G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanism of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.
18. Kooner JS, Baliga RR, Wilding J et al. Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. Arterioscler Thromb Vasc Biol 1998; 18: 1021-1026.
19. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 1998; 63: 134-141.
20. Belfiore F, Iannello S, Camuto M, Fagone S, Cavaleri A. Insulin sensitivity of blood glucose versus insulin sensitivity of blood free fatty acids in normal, obese, and obese-diabetic subjects. Metabolism 2001; 50: 573-582.
21. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130: 389-396.
22. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
23. Furlong NJ, McNulty SJ, O'Brien SV, Hardy KJ. Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycaemic agents; median follow-up 29 months. Pract Diab Int 2002; 19: 245-249.
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
25. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
26. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000; 43: 1507-1511.
27. Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LKM, Frayn KN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002; 51: 2467-2473.
28. Leslie P, Jung RT, Isles TE, Baty J. Energy expenditure in non-insulin-dependent subjects on metformin or sulfonylurea therapy. Clin Sci 1987; 73: 41-45.
29. Cigolini M, Bosello O, Zancanaro C, Orlandi PG, Fezzi O, Smith U. Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro. Diabetes Metab 1984; 10: 311-315.
30. Iannello S, Campione R, Belfiore F. Response of insulin, glucagon, lactate and nonesterified fatty acids in visceral obesity with and without NIDDM: relationship to hypertension. Mol Genet Metab 1998; 63: 214-223.
31. Reaven GM, Hollenbeck C, Jeng G-Y, Wu MS, Chen YDI. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020-1924.
32. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
33. Lovejoy J, Newby FD, Gebhart SSP, DiGirolamo M. Insulin resistance in obesity is associated with elevated basal lactate levels and diminished lactate appearance following intravenous glucose and insulin. Metabolism 1992; 41: 22-27.
34. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990; 13: 696-704.
35. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999; 22: 623-634.
36. Chen YD, Golay A, Swislocki AL, Reaven GM. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 17-21.
37. Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Arterioscler Thromb Vasc Biol 1997; 17: 64-71.
38. Widen EI, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992; 41: 354-358.
39. Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effect of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic syndrome. Clin Endocrinol 1999; 51: 231-236.
40. Charles MA, Eschewege E. Prevention of type 2 diabetes: role of Metformin. Drugs 1999; 58 (Suppl. 1): 71-73 and 75-82.
41. Abbasi F, Carantoni M, Chen YD, Reaven GM. Further evidence for a central role of adipose tissue in the antihyperglicemic effect of metformin. Diabetes Care 1998; 21: 1301-1305.